Attendee search 

1 in 3 people will develop cancer during their lifetime, and over 90% of cancer patient deaths are caused when the cancer spreads though the body, a process called metastasis. We have identified an excellent anti-metastatic target for therapy development. Extensive pre-clinical models have shown therapeutic efficacy of targeting an enzyme called Lysyl oxidase (LOX). In addition, LOX expression is clinically correlated with metastasis and poor survival in cancer patients. Moreover, LOX is implicated in fibrosis and initial pre-clinical studies suggest LOX may also be an effective therapeutic target for limiting fibrosis. We are currently developing new antibodies against LOX that we are testing pre-clinically with the intention to move into clinical trials in human patients. Our work thus has great potential to develop new effective therapies of commercial value, and offers a real potential to impact on patient well being and survival.

Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.

RetiCare IVS – Setting the sight on new treatments for retinal diseases

RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.

The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.

Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.

The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.

DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.

We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.

DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.

TOLREMO is an ETH Spin-off founded in March 2017. The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. The company’s innovative therapeutic approach specifically eradicates those cancer cells that ultimately cause drug resistance. Its science-based drug discovery and development pipeline is fueled by a unique screening platform for which a patent has been filed. TOLREMO’s vision is to use its personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.

- cancer drug resistance

- technology platform

- melanoma

- lung cancer

- pancreatic cancer

Seed Round closed in September 2017: CHF 2.4M

Virility Medical is a clinical stage venture, engaged in the development and commercialization of treatment for premature ejaculation by method of neuromodulation. Virility’s product is an intimate perineal skin patch. The patch carries an electronic module that delivers transcutaneous neuromuscular electrical stimulation to the adjacent nerves and muscles. Thus, the muscles are electrically inhibited and, the premature initiation of the ejaculation phase is delayed for the duration of stimulation, after which the patch is disposed of.

Sex Medicine

Neuromodulation

Premature Ejaculation

Electrical Stimulation

RetiCare IVS – Setting the sight on new treatments for retinal diseases

RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.

The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.

Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.

The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.